Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 86Lung Neoplasms 64Carcinoma, Non-Small-Cell Lung 50Neoplasm Metastasis 48Breast Neoplasms 48Glioma 41Glioblastoma 38Pancreatic Neoplasms 35Multiple Myeloma 35Brain Neoplasms 34Carcinoma, Renal Cell 33Lymphoma, Large B-Cell, Diffuse 29Melanoma 28Urinary Bladder Neoplasms 27Colorectal Neoplasms 27Squamous Cell Carcinoma of Head and Neck 25Ovarian Neoplasms 24Triple Negative Breast Neoplasms 21Oropharyngeal Neoplasms 21Carcinoma, Hepatocellular 21Lymphoma 20Mouth Neoplasms 18Lymphoma, Follicular 18Sarcoma 17Fallopian Tube Neoplasms 16Carcinoma, Transitional Cell 16Carcinoma 16Laryngeal Neoplasms 15Astrocytoma 15Lymphoma, Mantle-Cell 14

Interventions

Magnetic Resonance Spectroscopy 116-fluoroestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2/Neu Negative × Magnetic Resonance Spectroscopy × 1 year × Clear all
NCT02398773 2026-04-21

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

National Cancer Institute (NCI)

Phase 2 Active not recruiting
99 enrolled
Breast

HER2/Neu Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡